Set to be the first pre-revenue biotech to list in Hong Kong, Ascletis lays out priorities in IPO application
Ascletis is getting the ball rolling on the first pre-revenue biotech IPO in Hong Kong.
Hangzhou-based Ascletis, whose in-house hepatitis C drug is on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
